Abstract
Traditional Chinese Medicines (TCM) are rapidly gaining attention in the West as sources of new drugs, dietary supplements and functional foods. However, lack of consistent manufacturing practices and quality standards, fear of adulteration, and perceived deficiencies in scientific validation of efficacy and safety impede worldwide acceptance of TCM. In addition, Western pharmaceutical industries and regulatory agencies are partial toward single ingredient drugs based on synthetic molecules, and skeptical of natural product mixtures. This review concentrates on three examples of TCM-derived pharmaceuticals and functional foods that have, despite these usual obstacles, risen to wide acceptance in the West based on their remarkable performance in recent scientific investigations. They are: Sweet wormwood (Artemisia annua), the source of artemisinin, which is the currently preferred single compound anti-malarial drug widely used in combination therapies and recently approved by US FDA; Thunder god vine (Tripterygium wilfordii) which is being developed as a botanical drug for rheumatoid arthritis; and green tea (Camellia sinensis) which is used as a functional beverage and a component of dietary supplements.
Keywords: Artemisia annua, artemisinin, Camellia sinensis, (-)-epigallocatechin-3-gallate (EGCG), functional foods, nutraceuticals, traditional Chinese medicine (TCM), tripdiolide, Tripterygium wilfordii, triptolide
Current Drug Discovery Technologies
Title: Merging Traditional Chinese Medicine with Modern Drug Discovery Technologies to Find Novel Drugs and Functional Foods
Volume: 7 Issue: 1
Author(s): Rocky Graziose, Mary Ann Lila and Ilya Raskin
Affiliation:
- Rutgers University, 59 Dudley Rd., New Brunswick, NJ 08901, USA.
Keywords: Artemisia annua, artemisinin, Camellia sinensis, (-)-epigallocatechin-3-gallate (EGCG), functional foods, nutraceuticals, traditional Chinese medicine (TCM), tripdiolide, Tripterygium wilfordii, triptolide
Abstract: Traditional Chinese Medicines (TCM) are rapidly gaining attention in the West as sources of new drugs, dietary supplements and functional foods. However, lack of consistent manufacturing practices and quality standards, fear of adulteration, and perceived deficiencies in scientific validation of efficacy and safety impede worldwide acceptance of TCM. In addition, Western pharmaceutical industries and regulatory agencies are partial toward single ingredient drugs based on synthetic molecules, and skeptical of natural product mixtures. This review concentrates on three examples of TCM-derived pharmaceuticals and functional foods that have, despite these usual obstacles, risen to wide acceptance in the West based on their remarkable performance in recent scientific investigations. They are: Sweet wormwood (Artemisia annua), the source of artemisinin, which is the currently preferred single compound anti-malarial drug widely used in combination therapies and recently approved by US FDA; Thunder god vine (Tripterygium wilfordii) which is being developed as a botanical drug for rheumatoid arthritis; and green tea (Camellia sinensis) which is used as a functional beverage and a component of dietary supplements.
Export Options
About this article
Cite this article as:
Rocky Graziose, Mary Ann Lila and Ilya Raskin, Merging Traditional Chinese Medicine with Modern Drug Discovery Technologies to Find Novel Drugs and Functional Foods, Current Drug Discovery Technologies (2010) 7: 2. https://doi.org/10.2174/157016310791162767
DOI https://doi.org/10.2174/157016310791162767 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |

Related Articles
-
Anti-CCP Antibody Detection Facilitates Early Diagnosis and Prognosis of Rheumatoid Arthritis
Current Rheumatology Reviews Voltammetric Determination of Sinomenine in Biological Fluid Using a Glassy Carbon Electrode Modified by a Composite Film of Polycysteic Acid and Carbon Nanotubes
Combinatorial Chemistry & High Throughput Screening A Review of the Psychometric Properties and Use of the Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) in Clinical Research
Current Rheumatology Reviews Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs
Current Chemical Biology Chronotherapeutic Drug Delivery from Indomethacin Compression Coated Tablets for Early Morning Pain Associated Rheumatoid Arthritis
Current Drug Delivery Animal Models of Osteoarthritis
Current Rheumatology Reviews Pharmacology and Clinical Effect of Platonin, a Cyanine Photosensitizing Dye: Potential Molecular Targets
Current Pharmaceutical Biotechnology Current and Future Therapeutic Targets of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Current Drug Targets Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug
Current Drug Safety Activated Synovial Macrophages as Targets for Osteoarthritis Drug Therapy
Current Drug Targets The Effects of TNF α Antagonist Therapy on Bone Metabolism in Rheumatoid Arthritis: A Systematic Review
Current Drug Targets Pharmacophore-Based 3DQSAR and Molecular Docking Studies to Identify New Non-Peptidic Inhibitors of Cathepsin S
Current Medicinal Chemistry Immunomodulating Effects of Flavonoids on Acute and Chronic Inflammatory Responses Caused by Tumor Necrosis Factor α
Current Pharmaceutical Design The Medical Use of Wheatgrass: Review of the Gap Between Basic and Clinical Applications
Mini-Reviews in Medicinal Chemistry Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design Matrix Metalloproteinase Inhibitors: A Review on Pharmacophore Mapping and (Q)Sars Results
Current Medicinal Chemistry Survival Factors from Activated Accessory Cells and their Role in Triggering Autoimmune Diseases
Current Medicinal Chemistry Evidence of Association between Epstein Barr Virus Serum Antibodies with HAs and RI as Biomarkers of Active Rheumatoid Arthritis
Current Biomarkers (Under Re-organization) Will Pharmacogenetics Predict Response to Therapies in Rheumatoid Arthritis?
Current Pharmacogenomics